Many glycoproteins are heterogeneous, comprising a constant protein backbone with a variable composition of carbohydrate side chains. Since the advent of two-site immunometric assays employing monoclonal antibodies, problems with standardization of glycoprotein assays have been recognized.' These problems arise from differences between the structure of the reference standard and that of the endogenous antigen at or close to the antibody binding sites.
Many glycoproteins are heterogeneous, comprising a constant protein backbone with a variable composition of carbohydrate side chains. Since the advent of two-site immunometric assays employing monoclonal antibodies, problems with standardization of glycoprotein assays have been recognized.' These problems arise from differences between the structure of the reference standard and that of the endogenous antigen at or close to the antibody binding sites.
In this study we used the same two antibodies to optimize immunoradiometric assays (lRMAs) for human follicle stimulating hormone (hFSH) using two different reference preparations of the glycoprotein; the 2nd International Reference Preparation (lRP 78/549) and the recently available 1st International Standard (IS 83/575). As part of the assay validation, serum from defined clinical groups was analysed in both IRMAs and also in a reference radioimmunoassay (RIA) which had been standardized against both IRP 78/549 and IS 83/575.
MATERIALS AND METHODS
Production of mouse monoclonal antibodies to hFSH, partial purification of IgG, and preparation of polyclonal antibodies linked to Sepharose CL-4B were performed as previously described." Sheep anti-hFSH, donkey anti-rabbit IgG and normal animal serum (rabbit and sheep) were obtained from the Scottish Antibody Production Unit (SAPU, Law Hospital, Carluke, UK). A published method for hFSH RIA was ernployed.! Correspondence: Ms K A Smith.
The optimized two-site IRMA for hFSH was performed as follows: a range of hFSH standards [O-IOOU/L (IRP 78/549) or 0-400U/L (IS 83/575)] in assay buffer [0'025 mL; 0'05 mollL phosphate, pH 7· 4, 1070 (vIv) Tween 20, 4% (w/v) bovine serum albumin, 0'5% 'Y-globulin, 7· 7 mmollL sodium azide (lRP 78/549) or 0·1 mL; 0'1 mollL EPPS, pH8, 0·2% (v/v) Tween 20, 0'5% (v/v) normal sheep serum, 7' 7 mmollL sodium azide, 10% (vIv) horse serum (IS 83/575)] was incubated with 0'1 mL radioiodinated monoclonal anti-hFSH IgG for 16 h at ambient temperature. Post incubation, O' 1 mL of solid-phase sheep anti-hFSH IgG (1 mg/tube) was added, the tubes were mixed then shaken for 1 h at ambient temperature. Bound and free fractions were separated by centrifugation, using 3 x 3 . 5 mL washes with O' 15 mollL sodium chloride containing 0'2% (v/v) Tween 20. The bound fraction was counted for 60s by NEI600 multichannel gamma counter (Nuclear Enterprises, Edinburgh, UK) and the calibration curve calculated as previously described.! Clinically defmed serum samples were collected from selected subjects, serum separated and stored frozen until analysed. The clinical groups designated were: group I, male, 21-69 years (n=15); group 2, follicular phase, 21-42 years Figure 1 shows the hFSH concentrations for the clinically defined groups. For visual clarity the fourfold potency difference between IRP 78/549 and IS 83/575 has been accommodated on the ordinate axis of the figure; for statistical purposes IS 83/575 results were divided by four prior to comparison with IRP 78/549 results.
The mean hFSH results were unaffected either by immunoassay method (IRMA or RIA) or hFSH standard (IRP 78/549 or IS 83/575) for
Clinical group
Ideally, antibodies employed in immunometric assay should recognize the same epitopes on the reference preparation and the analyte being measured. Deviations from this ideal have been described for analytes present in pathological sera and this study demonstrates a similar problem in sera from normally menstruating women. Since the secreted forms of hFSH are known to vary during the menstrual cycle,' these results suggest that the monoclonal antibody employed in the IRMA recognizes those isoforms secreted at the time of ovulation less well than those secreted at other times. This effect is presumably related to alterations in the carbohydrate content at or close to the antibody binding site, and is more pronounced when IS 83/575 is the standard material.
These results highlight the potential pitfalls that can arise when using exquisitely specific monoclonal antibodies to assay heterogenous glycoproteins and underlines the possible dangers of employing reference intervals that have not been compiled from defined clinical groups for each individual assay. The clinical biochemist should therefore be aware that the nature of the antibody employed and the standard preparation used contribute significantly to method dependent bias, a problem that has recently been recognized in the UK External Quality Assessment Scheme." 
